These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 16127653)
1. Antisense oligonucleotides for target validation and gene function determination. Taylor MF IDrugs; 1999 Aug; 2(8):777-81. PubMed ID: 16127653 [TBL] [Abstract][Full Text] [Related]
2. Application of antisense oligonucleotides for gene functionalization and target validation. Bennett CF; Cowsert LM Curr Opin Mol Ther; 1999 Jun; 1(3):359-71. PubMed ID: 11713801 [TBL] [Abstract][Full Text] [Related]
3. Tools for target identification and validation. Wang S; Sim TB; Kim YS; Chang YT Curr Opin Chem Biol; 2004 Aug; 8(4):371-7. PubMed ID: 15288246 [TBL] [Abstract][Full Text] [Related]
4. Antisense and RNAi: powerful tools in drug target discovery and validation. Lavery KS; King TH Curr Opin Drug Discov Devel; 2003 Jul; 6(4):561-9. PubMed ID: 12951819 [TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination. Taylor MF; Wiederholt K; Sverdrup F Drug Discov Today; 1999 Dec; 4(12):562-567. PubMed ID: 10557138 [TBL] [Abstract][Full Text] [Related]
6. Genomics in drug discovery: the best things come to those who wait. Bansal AT; Barnes MR Curr Opin Drug Discov Devel; 2008 May; 11(3):303-11. PubMed ID: 18428083 [TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
8. The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets. Hardy LW; Peet NP Drug Discov Today; 2004 Feb; 9(3):117-26. PubMed ID: 14960389 [TBL] [Abstract][Full Text] [Related]
9. siRNA-based approaches in cancer therapy. Devi GR Cancer Gene Ther; 2006 Sep; 13(9):819-29. PubMed ID: 16424918 [TBL] [Abstract][Full Text] [Related]
10. RNAi: a novel antisense technology and its therapeutic potential. Dallas A; Vlassov AV Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063 [TBL] [Abstract][Full Text] [Related]
11. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery. Fischer HP Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773 [TBL] [Abstract][Full Text] [Related]
12. The role of antisense oligonucleotides in the wave of genomic information. Baker BF Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):397-9. PubMed ID: 11563054 [TBL] [Abstract][Full Text] [Related]
13. In silico determination of potential antisense targets for human beta-globin variants. Arrigo P; Ivaldi G; Cardo PP In Silico Biol; 2002; 2(2):143-50. PubMed ID: 12066838 [TBL] [Abstract][Full Text] [Related]
14. Analysis of RNA-protein interactions by flow cytometry. Brodsky AS; Johnston AP; Trau M; Silver PA Curr Opin Mol Ther; 2003 Jun; 5(3):235-40. PubMed ID: 12870432 [TBL] [Abstract][Full Text] [Related]
15. Array-based proteomics: high-throughput expression and purification of IMAGE consortium cDNA clones. Albala JS; Humphery-Smith I Curr Opin Mol Ther; 1999 Dec; 1(6):680-4. PubMed ID: 19629864 [TBL] [Abstract][Full Text] [Related]